Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China.
Department of Blood Transfusion, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China.
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):600-606. doi: 10.1016/j.ejso.2020.01.017. Epub 2020 Jan 15.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a standard treatment for pseudomyxoma peritonei (PMP) recommended by Peritoneal Surface Oncology Group International (PSOGI). The study is to analyze the incidence of perioperative serious adverse events (SAEs) of CRS + HIPEC to treat PMP patients, and identify the risk factors, for guiding the prevention of SAEs.
This is a retrospective study on the PMP database established at our center. The clinicopathological features, treatment details and SAEs information on the PMP patients are systematically established in this database. The incidence, organ system distribution and severity of perioperative SAEs are analyzed. Univariate and multivariate analyses are performed to identify the independent risk factors.
Among the 272 CRS + HIPEC procedures for 254 PMP patients, there are 93 (34.2%) SAEs. Six systems are involved in the SAEs, including infections (9.6%), digestive system (8.1%), respiratory system (6.3%), cardiovascular system (5.5%), hematological system (2.9%), and urinary system (1.5%), in terms of frequency. In terms of severity, the majority is grade III SAEs (27.9%), followed by grade IV SAEs (4.8%) and grade V SAEs (1.5%). Univariate analysis reveals 4 risk factors for perioperative SAEs: HIPEC regimens (P = 0.020), PCI (P = 0.025), intraoperative red blood cell transfusion volume (P = 0.004), and intraoperative blood loss volume (P = 0.002). Multivariate and logistic regression model analysis identifies only one independent risk factor for perioperative SAEs: intraoperative blood loss volume (P = 0.001, OR = 0.344, 95%CI: 0.182-0.649).
PMP patients treated by CRS + HIPEC at experienced centers could have acceptable safety. Improving the surgical techniques and developing the integrated hemostasis techniques are essential to reduce intraoperative blood loss and decrease SAEs rate.
细胞减灭术(CRS)和腹腔热灌注化疗(HIPEC)是腹膜表面肿瘤国际协会(PSOGI)推荐的治疗假性黏液瘤腹膜(PMP)的标准治疗方法。本研究旨在分析 CRS+HIPEC 治疗 PMP 患者围手术期严重不良事件(SAE)的发生率,并确定风险因素,以指导预防 SAE。
这是对我们中心建立的 PMP 数据库进行的回顾性研究。该数据库系统地建立了 PMP 患者的临床病理特征、治疗细节和 SAE 信息。分析了围手术期 SAE 的发生率、器官系统分布和严重程度。进行了单因素和多因素分析,以确定独立的风险因素。
在 254 例 PMP 患者的 272 例 CRS+HIPEC 手术中,有 93 例(34.2%)发生 SAE。SAE 涉及 6 个系统,包括感染(9.6%)、消化系统(8.1%)、呼吸系统(6.3%)、心血管系统(5.5%)、血液系统(2.9%)和泌尿系统(1.5%),按频率排列。按严重程度排列,大多数为 3 级 SAE(27.9%),其次为 4 级 SAE(4.8%)和 5 级 SAE(1.5%)。单因素分析显示,围手术期 SAE 的 4 个风险因素为:HIPEC 方案(P=0.020)、PCI(P=0.025)、术中红细胞输血量(P=0.004)和术中出血量(P=0.002)。多因素和逻辑回归模型分析仅确定了围手术期 SAE 的一个独立风险因素:术中出血量(P=0.001,OR=0.344,95%CI:0.182-0.649)。
在有经验的中心接受 CRS+HIPEC 治疗的 PMP 患者安全性可接受。提高手术技术和开发综合止血技术对于减少术中出血量和降低 SAE 发生率至关重要。